Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Darinaparsin

Generic Name: Darinaparsin

Drug Type: Small Molecule

Chemical Formula: C_₁₂H_₂₂AsN_₃O_₆S

CAS Number: 69819-86-9

Unique Ingredient Identifier: 9XX54M675G

Overview

No overview information available.

Background

No background information available.

Indication

Investigated for use/treatment in blood (blood forming organ disorders, unspecified), cancer/tumors (unspecified), solid tumors, multiple myeloma, and liver cancer.

Associated Conditions

No associated conditions information available.

Clinical Trials

Safety Study of Darinaparsin in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) to Treat Lymphoma

Phase 1

Withdrawn

Posted: 2010/06/08

Sponsor:Alaunos Therapeutics

ID:NCT01139359

Study of Oral Darinaparsin in Patients With Advanced Solid Tumors

Phase 1

Completed

Posted: 2010/06/08

Sponsor:Alaunos Therapeutics

ID:NCT01139346

Phase I Trial of ZIO-101 in Patients With Solid Tumors

Phase 1

Completed

Posted: 2007/07/31

Sponsor:M.D. Anderson Cancer...

ID:NCT00509782

A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma

Phase 2

Posted: 2007/01/18

Sponsor:Alaunos Therapeutics

ID:NCT00423306

Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers

Phase 2

Completed

Posted: 2007/01/11

Sponsor:Alaunos Therapeutics

ID:NCT00421213

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy